Company Uses Intravenous Stem Cells to Successfully Treat Alzheimer’s
An intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease has been successfully performed by Stemedica International, a subsidiary of Stemedica Cell Technologies, developing stem cell therapies for Alzheimer’s disease and dementia. The first results of the…